Last €7.40 EUR
Change Today +0.09 / 1.23%
Volume 54.1K
THR On Other Exchanges
EN Brussels
As of 11:35 AM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

thrombogenics nv (THR) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/25/14 - €24.00
52 Week Low
10/16/14 - €6.02
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for THROMBOGENICS NV (THR)

Related News

No related news articles were found.

thrombogenics nv (THR) Related Businessweek News

No Related Businessweek News Found

thrombogenics nv (THR) Details

ThromboGenics NV, an integrated biopharmaceutical company, is engaged in developing and commercializing ophthalmic and oncology medicines in Belgium and interntionally. The company offers JETREA for the treatment of symptomatic vitreomacular traction. It has a collaboration agreement with BioInvent International AB to develop anti-factor VIII, an anti-coagulation treatment for various indications, such as the prevention and treatment of deep vein thrombosis, and the treatment of atrial fibrillation; and anti-placental growth factor, an anti-angiogenic component for the treatment of various disorders, including cancer, age-related macula degeneration, retinopathy, and inflammation. The company also has a research and license agreement with Bharat Biotech; a production agreement with Fujifilm Diosynth Biotechnologies UK Limited; a license agreement Grifols and NuVue Technologies, Inc.; a life sciences research partnership with VZW; agreements with Eleven Biotherapeutics, Bicycle Therapeutics, and Flanders Institute for Biotechnology; and cooperation agreements with Centrum voor Moleculaire en Vasculaire Biologie and KULeuven. ThromboGenics NV was founded in 1991 and is headquartered in Leuven, Belgium.

154 Employees
Last Reported Date: 04/9/14
Founded in 1991

thrombogenics nv (THR) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: €448.0K
Compensation as of Fiscal Year 2013.

thrombogenics nv (THR) Key Developments

ThromboGenics NV Nominates Emmanuele Attout as Independent Non-Executive Director

ThromboGenics NV announced that its Board of Directors has nominated Emmanuele Attout to be its new Independent non-executive director. Mrs. Attout will join the Audit Committee of the company. Mrs. Attout has been an audit partner at PricewaterhouseCoopers since 1994. She has been in charge of audits of a range of clients including banks, insurance companies, investment funds and assets managers. She has in recent years been in charge of the audits of listed pharmaceuticals companies and life sciences business out of which she brings substantial relevant experience to the Board and to the Audit Committee.

ThromboGenics NV Appoints Dominique Vanfleteren as New Chief Financial Officer

ThromboGenics NV announced the appointment of Dominique Vanfleteren as its new Chief Financial Officer (CFO) with immediate effect. Dominique Vanfleteren has over 25 years of experience in senior finance, operational, control and reporting roles within quoted international biopharmaceutical companies. Before joining ThromboGenics, Dominique spent 12 years at UCB, a global biopharmaceutical company, where he held a number of international managerial finance positions, the latest being the CFO of UCB's Asia Pacific Operations, operating from Brussels and Shanghai. Prior to joining UCB, Dominique worked for GSK during 16 years. He held a number of senior finance positions in Brussels and London, his latest being Finance Director of GSK's Diversified Healthcare Services Europe.

ThromboGenics NV Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-15-2015 10:00 AM

ThromboGenics NV Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-15-2015 10:00 AM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Patrik De Haes, Chief Executive Officer and Executive Director.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
THR:BB €7.40 EUR +0.09

THR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for THR.
View Industry Companies

Industry Analysis


Industry Average

Valuation THR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.7x
Price/Book 0.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact THROMBOGENICS NV, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at